Contribute Try STAT+ Today

The biggest question in biotech — other than whether Covid-19 vaccines will work — centers on Biogen and its yearslong quest to win Food and Drug Administration approval for a polarizing treatment for Alzheimer’s disease.

Last week set the stage for the debate ahead. First, the FDA’s internal clinical review team argued that Biogen’s mixed bag of supporting data was strong enough to justify approving the drug, called aducanumab. Then, a panel of independent experts reviewed the same data and came to a starkly opposite conclusion, with 10 of 11 panelists voting that Biogen hadn’t adequately proved aducanumab’s efficacy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy